Introduction {#Sec1}
============

The incidence of colorectal cancer (CRC) has increased gradually over the decades in developed countries, and CRC now is the third most-commonly diagnosed cancer \[[@CR1]\]. Recent progress in active cytotoxic chemotherapy regimens has contributed to prolonged survival of patients with CRC \[[@CR2], [@CR3]\]. However, to reduce mortality, there is a growing need for early prediction of prognosis to further improve postoperative interventions.

Since Dukes \[[@CR4]\] reported the histopathological grading of rectal cancer in 1937, accumulated evidence on CRC has confirmed the clinical importance of lymph node (LN) status. In particular, the number of metastatic LNs (MLNs) has been considered one of the most powerful predictors in CRC \[[@CR5], [@CR6]\] and guides the indication for adjuvant chemotherapy. On the other hand, many researchers have proposed alternatives to indicate LN status, including the total number of dissected LNs (DLNs) \[[@CR7]--[@CR10]\], LN ratio (LNR) \[[@CR11]--[@CR15]\], and extramural cancer deposits (EX) \[[@CR16], [@CR17]\]. However, to date, published studies rarely have focused on the histopathological characteristics of MLNs.

More recently, a novel histological grading system using poorly differentiated clusters (PDCs), which are composed of ≥5 cancer cells that present at the invasive front of the tumor and lack full glandular formation, has been highlighted as a histopathological prognosticator of CRC \[[@CR18]--[@CR20]\]. Presence of PDCs was reported to be strongly positively correlated with LN metastasis and poorer survival and, consequently, was expected to provide a complementary approach to the conventional pathological diagnostic process. However, despite increasing evidence of PDCs as prognostic indicators, no previous studies have focused on PDCs in MLNs and their correlation to PDCs in primary tumors. An understanding of the histopathological behavior of PDCs in MLNs may provide insights into the key process following LN metastasis. Therefore, this study expanded upon the PDC concept of evaluation for histopathological features of MLNs and aimed to clarify the clinicopathological importance of PDCs in MLNs in comparison with previously reported LN status.

Patients and methods {#Sec2}
====================

Patients {#Sec3}
--------

This study examined data on patients with pathological Stage III (pStage III) CRC who had undergone potentially curative resection and systematic en bloc LN dissection at a single institution from 2000 to 2012. Since laparoscopic surgery became widespread during that period, cases in this study were treated with either open or laparoscopic surgery. Following the recommendation of the Union for International Cancer Control (UICC) TNM classification \[[@CR5]\] to eliminate possible staging migration, patients with \<12 DLNs were ineligible for this study. In addition, although pelvic sidewall LN dissection, which means removal of internal iliac and obturator LNs, traditionally has been performed in Japan for locally advanced lower rectal cancer \[[@CR21], [@CR22]\], patients on whom that dissection method had been performed were excluded. Other exclusion criteria for this retrospective cohort included (1) synchronous or multiple cancers, (2) preoperative therapy (neoadjuvant chemotherapy and endoscopic resection), (3) cancers related to ulcerative colitis or Crohn's disease, and (4) familial adenomatous polyposis or hereditary non-polyposis colorectal cancer. To be included for analysis, after resection, patients were required to have follow-up surveillance at 3-month intervals for 1 year, then every 6 months for 3 years, and yearly thereafter. Prior to the study's initiation, approval to use patient data for research purposes was obtained at the institution.

Specimens {#Sec4}
---------

Within an hour after resection, all regional LNs were manually retrieved from the en bloc resected specimens after visual observation and palpation. The process of sectioning specimens after formalin fixation was performed according to Japanese guidelines \[[@CR6]\]. In particular, larger retrieved LNs were longitudinally cut through the hilus, and smaller ones were embedded in paraffin whole. Sections 3 μm thick were cut from paraffin-embedded specimens and mounted onto glass slides. After deparaffinization, slides were stained with conventional hematoxylin and eosin according to the standard procedure.

Histopathological evaluation {#Sec5}
----------------------------

According to criteria set previously \[[@CR18], [@CR19]\], PDCs were defined as cancer clusters lacking full glandular formation and composed of ≥5 cancer cells, which are commonly observed at the invasive front of the tumor. All slides were reviewed pathologically, with special attention paid to the presence of PDCs, and ≥10 PDCs under a microscopic field with a ×20 objective lens were defined as positive PDCs. Our previous study \[[@CR23]\] reported representative slides of PDCs in primary tumors. In the present study, PDCs in primary tumors were evaluated at the invasive front, whereas PDCs in MLNs were evaluated where they were observed most commonly (Fig. [1](#Fig1){ref-type="fig"}), and the number of MLNs with positive PDCs (MLNs-PDCs) was counted.Fig. 1Representative examples of metastatic lymph nodes with positive PDCs under low-power view (**a**) and under the view of ×20 objective lens using hematoxylin and eosin stain (**b**). PDCs (\>10) are observed (*arrowheads*). The *scale bar* indicates 200 μm

In addition to a pathologically proven number of DLNs, the LNR, defined as the number of MLNs divided by the number of DLNs, was assessed as LN status. For EX lacking residual LN structure, the study adopted the definition in Japanese guidelines \[[@CR6]\]; consequently, EX were comprehensively considered as MLNs. However, tumor nodules that might be related to an isolated cancer focus in the lymphovascular vessels or perineural space were not considered as MLNs \[[@CR16]\].

In addition, other pathological variables were obtained by observing slides. All slides were evaluated by a trained pathologist specializing in gastrointestinal pathology and blinded to the patients' outcome.

Statistical analysis {#Sec6}
--------------------

Overall survival (OS) curves were drawn by the Kaplan-Meier method, and comparisons between groups were performed using the log-rank test, with the length of the follow-up period being truncated at 5 years. In addition, the cutoff for each LN status was optimized by maximizing the significance. Correlation analysis was performed using the Spearman rank correlation coefficient. Multivariate Cox proportional hazard regression analysis was developed using stepwise regression among representative variables, and the hazard radio (HR) and 95 % confidence interval (CI) for each variable were calculated. Furthermore, adequacy of the parametric model was assessed by the Akaike information criterion (AIC) \[[@CR24]\] to estimate the most fitting model with the smallest information loss and to compare models consisting of various combinations of variables. Differences were considered statistically significant at the *p* \< 0.05 level.

All statistical calculations were performed by EZR statistical software (Saitama Medical Center, Jichi Medical University, Saitama, Japan) \[[@CR25]\], which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria).

Results {#Sec7}
=======

The study enrolled 159 patients. As Table [1](#Tab1){ref-type="table"} shows, 111 tumors (70 %) were colonic and 48 (30 %) were rectal. Most patients had pT3 or pT4 lesions (90 %), and half had positive-PDC primary tumors (50 %). One hundred seven patients (69 %) received adjuvant chemotherapy consisting mainly of 5-fluorouracil (5-FU); however, 52 (31 %) did not. At the time of this study, the median follow-up was 48.5 months and the 5-year OS rate of this cohort was 79 %. On average, there were 22.7 DLNs; of those, 2.8 MLNs and 1.0 MLN-PDCs were detected pathologically. No difference was found between open and laparoscopic surgery in the number of DLNs and MLNs (mean DLNs, 23.5 vs. 21.7, respectively; mean MLNs, 3.1 vs. 2.6, respectively). The study found a moderately positive correlation between the number of MLNs-PDCs and number of MLNs and a slight correlation between the number of MLNs with positive and negative PDCs. Figure [2](#Fig2){ref-type="fig"} shows scatter plots for the number of MLNs-PDCs and MLNs.Table 1Patients and tumor characteristics (*n* = 159)VariablesAge (year) \[mean (range, SD)\]65.2 (21--94, 11.9)Sex \[*n* (%)\] Male76 (55) Female83 (45)Tumor location \[*n* (%)\]Colon Cecum-transverse51 (32) Descending-sigmoid60 (38)Rectum48 (30)Tumor size (mm) \[mean (range, SD)\]47 (10--110, 19.4)T status \[*n* (%)\] pT11 (1) pT215 (9) pT3105 (66) pT438 (24)PDCs in primary tumor \[*n* (%)\] Positive80 (50) Negative79 (50)DLNs \[mean (range, SD)\]22.7 (12--91, 11.7)MLNs \[mean (range, SD)\]2.8 (1--18, 2.7)LNR \[median (IQR)\]0.09 (0.06--0.17)MLNs-PDCs \[mean (range, SD)\]1.0 (0--8, 1.4)Operative approach \[*n* (%)\]Open83 (52)Laparoscopic76 (48)Adjuvant chemotherapy \[*n* (%)\] With107 (69) Without52 (31)*PDCs* poorly differentiated clusters, *DLNs* dissected lymph nodes, *MLNs* metastatic lymph nodes, *LNR* lymph node ratio, *MLNs-PDCs* metastatic lymph nodes with positive PDCsFig. 2**a** Scatter plots for the number of MLNs-PDCs and the number of MLNs. The graph shows a moderate correlation between the two (Spearman rank correlation coefficient 0.405, *p* \< 0.0001). **b** Scatter plots for the number of MLNs with positive and negative PDCs. Little correlation is found between the two (Spearman rank correlation coefficient 0.145, *p* = 0.068)

Based on the Kaplan-Meier survival method, univariate analysis identified a cutoff of 5 MLNs (86 vs. 55 %, *p* = 0.024), 2 MLNs-PDCs (85 vs. 63 %, *p* = 0.008), and LNR of 30 % (85 vs. 44 %, *p* = 0.036) as the statistically reliable stratifications to discriminate patient survival (Fig. [3](#Fig3){ref-type="fig"}). Given this, we decided upon ≥5 MLNs, ≥2 MLNs-PDCs, and ≥30 % LNR to indicate positive LN status for subsequent analysis. On the other hand, when the study analyzed from 13 to 91 DLNs, a statistical threshold for 5-year OS was not obtained. Table [2](#Tab2){ref-type="table"} shows comparison of clinicopathological variables between patients with ≥2 MLNs-PDCs and \<2. MLNs-PDCs (≥2) were associated with pT4 tumors (*p* = 0.0035), open surgery (*p* = 0.016), a greater number of MLNs (*p* \< 0.0001), and a positive-PDC primary tumor (*p* \< 0.0001). When the combination of PDC status in primary tumors and the number of MLNs-PDCs was examined, there were only two (3 %) negative-PDC primary tumors among those with ≥2 MLNs-PDCs. In contrast, of patients with \<2 MLNs-PDCs, 53 (41 %) had positive-PDC primary tumors and 77 (59 %) had negative-PDC ones.Fig. 3Comparison of survival curves for each lymph node statusTable 2Comparison of variables between patients with ≥2 and \<2 MLNs-PDCsVariables≥2 MLNs-PDCs (n = 29)\<2 MLNs-PDCs (*n* = 130)P valueAge (year) \[mean (range, SD)\]66.5 (21--95, 14.0)65.0 (21--85, 11.4)Sex \[*n* (%)\] Male15 (10)61 (38)0.64 Female14 (9)69 (43)Tumor location \[*n* (%)\]Colon0.11 Cecum-transverse12 (8)39 (25) Descending-sigmoid6 (4)54 (34)Rectum11 (7)37 (24)Tumor size (mm) \[mean (range, SD)\]54 (20--110, 24.3)45 (20--110, 18.0)0.16T status \[*n* (%)\] pT10 (0)1 (1)0.0035 (T1--3 vs. T4) pT20 (0)15 (9) pT316 (10)89 (56) pT413 (8)25 (16)PDCs in primary tumor \[*n* (%)\] Positive27 (17)53 (33)\<0.0001 Negative2 (1)77 (48)DLNs \[mean (range, SD)\]23.9 (12--85, 14.4)22.4 (12--91, 11.1)0.68MLNs \[mean (range, SD)\]5.51 (2--18, 3.55)2.19 (1--13, 1.95)\<0.0001LNR \[median (IQR)\]0.24 (0.13--0.37)0.08 (0.05--0.14)\<0.0001Operative approach \[*n* (%)\] Open21 (13)62 (39)0.016 Laparoscopic8 (5)68 (43)Adjuvant chemotherapy \[*n* (%)\] With22 (14)85 (53)0.28 Without7 (4)45 (28)

Furthermore, in the subgroup analysis for the 128 patients with \<5 MLNs, the 5-year OS rates of the patients with ≥2 (*n* = 14) and \<2 MLNs-PDCs (*n* = 114) were 68 and 88 % (*p* = 0.037). In contrast, in subgroup analysis for the 26 patients with ≥5 MLNs, there was no significant difference in the 5-year OS rates between the patients with ≥2 and \<2 MLNs-PDCs (59 and 53 %; *p* = 0.70). In addition, in another subgroup analysis for patients who received adjuvant chemotherapy and those who did not, 5-year OS rates of patients with and without chemotherapy were 67 vs. 64 % in ≥2 MLNs-PDCs and 87 vs. 82 % in \<2 MLNs-PDCs, and no significant difference was found between the groups.

As Table [3](#Tab3){ref-type="table"} shows, among the representative clinicopathological variables, including LN status, the following five variables were identified using the AIC in multivariate analysis: tumor location (rectum vs. colon), number of MLNs-PDCs (≥2 vs. \<2), sex (female vs. male), tumor size (≥50 vs. \<50 mm), and T status (pT4 vs. pT1--3). Consequently, both pT4 tumors (HR = 3.54, *p* \< 0.001) and ≥2 MLNs-PDCs (HR = 2.50, *p* = 0.038) were revealed as significant prognosticators for 5-year OS. Finally, the prognostic model incorporating ≥2 MLNs-PDCs had higher accuracy with lower AIC value (AIC = 230.08) than models incorporating other indicators of LN status, such as ≥5 MLNs (AIC = 231.21) or ≥30 % LNR (AIC = 231.77).Table 3Univariate and multivariate survival analysis of histological valuablesVariablesUnivariate^a^Multivariate^b^*p* ValueHR95 % CI*p* ValueAge (year) (≥65 vs. \<65)0.29------Sex (female vs. male)0.232.150.88--5.240.093Tumor location (rectum vs. colon)0.0722.230.98--5.050.055Tumor size (≥50 vs. \<50 mm)0.702.200.89--5.450.089T status (T4 vs. T1--3)0.0323.541.37--9.140.009MLNs (≥5 vs. \<5)0.024------LNR (≥30 vs. \<30 %)0.004------MLNs-PDCs (≥2 vs. \<2)0.0082.501.09--5.740.031Adjuvant chemotherapy (without vs. with)0.31------^a^Kaplan and Meier method, and statistical significance was determined by log-rank test^b^Multivariate survival analysis was performed using Cox's proportional hazard model*HR* hazard ratio, *CI* confidence interval

Discussion {#Sec8}
==========

The present study examined prognostic properties of the number of MLNs-PDCs in a retrospective cohort comprising 159 patients with pStage III CRC. Since the clinical importance of PDCs in primary tumors has been clarified successfully \[[@CR18], [@CR19], [@CR23], [@CR26]\], criteria modified by the authors was applied to investigate histopathological features in MLNs. To our knowledge, this is the first study to highlight the histopathological features of PDCs in MLNs as a candidate for a new LN status.

Results showed that ≥2 MLNs-PDCs were associated closely with PDC-positive primary tumors, implying that PDC status in metastatic sites frequently could parallel that in primary tumors. On the other hand, this study found that some PDC-positive tumors were not accompanied by PDC-positive MLNs. Using similar approaches, Takahashi et al. \[[@CR27]\] found histopathological heterogeneity between primary tumors and their synchronous MLNs in CRC patients. Furthermore, it is worth mentioning that Mori et al. \[[@CR28]\] demonstrated that histopathological heterogeneity between primary tumors and their synchronous MLNs was associated with poorer survival even after adjuvant chemotherapy was administered. However, in the subgroup of this study that examined the effect of adjuvant chemotherapy, no significant difference was found between patients with ≥2 and \<2 MLNs-PDCs. It is possible that this inconsistent result is due to the small sample size. Another possible explanation is that there was no control over the chemotherapy regimens given to patients, since those regimens progressed from single-dose 5-FU to combinations using 5-FU and oxaliplatin or irinotecan or both \[[@CR2], [@CR3]\] over the period of this study. In this context, additional prospective studies using larger sample sizes would confirm our results.

The most important finding of this study was that ≥2 MLNs-PDCs were associated strongly with a poorer 5-year OS. Although the number of MLNs-PDCs was correlated moderately positively with the number of MLNs, the number of MLNs-PDCs could provide the highest degree of discrimination regarding patient survival compared with the number of MLNs and other measures of LN status that are based on the theory of AIC. These findings suggest that the number of MLNs-PDCs could provide more precise information on potential tumor aggressiveness at the metastatic site. Furthermore, this study assessed the subgroups of patients with \<5 MLNs, and there was significant difference in the 5-year OS rates between patients with ≥2 and \<2 MLNs-PDCs. Consequently, this outcome suggests that MLNs-PDCs might contribute to further survival stratification, especially for CRC patients with \<5 MLNs. Interestingly, Komuta et al. \[[@CR29]\] and Fujii et al. \[[@CR30]\] reported the "extracapsular invasion" of MLNs, which was highly indicative of tumor aggressiveness at the metastatic site. This concept seems to be similar to that of PDCs in MLNs in our study. Likewise, Ueno et al. \[[@CR16]\] described EX that exhibited active, invasive lesions as "aggressive EX," which was associated with a dramatically worse prognosis. Since evaluation criteria in this study allowed EX to be comprehensively considered as MLNs, it is possible that MLNs with positive PDCs included some aggressive EX.

This study has some potential limitations. First, the 5-year OS rate of 79 % in patients with pStage III CRC in this cohort seems to be relatively better than that estimated in studies with larger populations \[[@CR2], [@CR3]\]. The reason for this remains unclear. Second, the exceedingly high hazard ratio may be a product of the single-institution experience and the relatively small sample size in this study. Another question is why ≥2 MLNs-PDCs were related to open surgery (*p* = 0.016) even though the number of DLNs and MLNs did not differ statistically between open and laparoscopic surgery. One possible explanation is surgeons' preoperative choices, in which cases with clinically diagnosed T4 tumors were treated by open surgery. In addition, although cumulative evidence has confirmed a larger number of MLNs as a strong prognosticator of CRC, cutoff thresholds for some LN statuses addressed in this study remain under intense discussion. With respect to the cutoff threshold of LNR, Yuan et al. \[[@CR13]\] defined it as 33 %, Gleisner et al. \[[@CR14]\] as 50 %, and Madbouly et al. \[[@CR15]\] as 38 %. Although consensus has not been reached regarding this cutoff, they agreed that a higher LNR was an adverse prognosticator. The cutoff of 30 % in this study seems to be comparable to aforementioned data. In contrast, similar to the experience of Kotake et al. \[[@CR10]\], we did not identify a statistically reliable cutoff for the number of DLNs. Although existing guidelines \[[@CR5], [@CR6]\] recommend that ≥12 DLNs be examined to eliminate possible staging migration, some researchers claim that there is no minimum number of DLNs that would enhance the accuracy of staging pStage III CRC \[[@CR8], [@CR9]\]. Therefore, this issue merits further discussion.

Conclusion {#Sec9}
==========

The PDCs in MLNs were closely associated with that in primary tumors. The number of MLNs-PDCs could exert an effect on survival and provide more concise information to improve stratification in pStage III CRC and, consequently, could be a candidate for a new, alternative LN status. This study demonstrated the need for special observation of PDCs in MLNs during pathological diagnosis.
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